Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q6ZVT0
UPID:
TTL10_HUMAN
Alternative names:
Tubulin--tyrosine ligase-like protein 10
Alternative UPACC:
Q6ZVT0; B1AMF6; Q5T2W4; Q5T2W5; Q8N9X2
Background:
Inactive polyglycylase TTLL10, also known as Tubulin--tyrosine ligase-like protein 10, plays a unique role in cellular functions despite its classification as inactive. This protein, encoded by the gene with the UniProt accession number Q6ZVT0, adds complexity to the understanding of post-translational modifications.
Therapeutic significance:
Understanding the role of Inactive polyglycylase TTLL10 could open doors to potential therapeutic strategies. Its involvement in cellular mechanisms, despite being labeled as inactive, suggests untapped avenues for drug discovery and disease treatment.